tetano
Editor, Senior Moderator
Med J Aust. 2014 Jul 21;201(2):109-11.
Influenza vaccine effectiveness in Australia: results from the Australian Sentinel Practices Research Network.
Sullivan SG1, Chilver MB2, Higgins G3, Cheng AC4, Stocks NP2.
Author information
Abstract
Objective: To estimate influenza vaccine coverage and effectiveness against medically attended laboratory-confirmed influenza for the 2012 season. Design, setting and participants: Test-negative design involving patients recruited as part of the Australian Sentinel Practices Research Network, a network of sentinel general practitioners throughout Australia. Throughout 2012, at the discretion of the GP at one of 102 participating practices, patients presenting with influenza-like illness were swabbed and included in the study. Main outcome measure: Influenza vaccine effectiveness (VE) estimated as (1 - OR)*100% by logistic regression. Results: 1775 patients were swabbed. The epidemic period was identified as Weeks 10 to 43 of 2012. After exclusions, there were 1414 patients for the VE analysis, including 593 (42%) who tested influenza-positive and 821 who tested negative. 27% of test-negative patients were vaccinated, of whom most were aged 50 years and over. The overall VE, adjusted for age group, month of presentation and state or territory, was 23% (95% CI, - 4% to 43%) against all influenza types, 15% (95% CI, - 17% to 38%) against influenza A, 13% (95% CI, - 20% to 36%) against influenza A(not H1) and 53% (95% CI, 5% to 77%) against influenza B. Conclusion: Vaccination against influenza was modestly protective, reducing the risk of medical presentation with influenza by around 23%.
PMID:
25045991
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/25045991
Influenza vaccine effectiveness in Australia: results from the Australian Sentinel Practices Research Network.
Sullivan SG1, Chilver MB2, Higgins G3, Cheng AC4, Stocks NP2.
Author information
Abstract
Objective: To estimate influenza vaccine coverage and effectiveness against medically attended laboratory-confirmed influenza for the 2012 season. Design, setting and participants: Test-negative design involving patients recruited as part of the Australian Sentinel Practices Research Network, a network of sentinel general practitioners throughout Australia. Throughout 2012, at the discretion of the GP at one of 102 participating practices, patients presenting with influenza-like illness were swabbed and included in the study. Main outcome measure: Influenza vaccine effectiveness (VE) estimated as (1 - OR)*100% by logistic regression. Results: 1775 patients were swabbed. The epidemic period was identified as Weeks 10 to 43 of 2012. After exclusions, there were 1414 patients for the VE analysis, including 593 (42%) who tested influenza-positive and 821 who tested negative. 27% of test-negative patients were vaccinated, of whom most were aged 50 years and over. The overall VE, adjusted for age group, month of presentation and state or territory, was 23% (95% CI, - 4% to 43%) against all influenza types, 15% (95% CI, - 17% to 38%) against influenza A, 13% (95% CI, - 20% to 36%) against influenza A(not H1) and 53% (95% CI, 5% to 77%) against influenza B. Conclusion: Vaccination against influenza was modestly protective, reducing the risk of medical presentation with influenza by around 23%.
PMID:
25045991
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/25045991